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original work is proObjective: The objective of this study is to estimate life expectancies of HIV-positive
patients conditional on response to antiretroviral therapy (ART).
Methods: Patients aged more than 20 years who started ART during 2000–2010
(excluding IDU) in HIV clinics contributing to the UK CHIC Study were followed for
mortality until 2012. We determined the latest CD4þ cell count and viral load before ART
and in each of years 1–5 of ART. For each duration of ART, life tables based on estimated
mortality rates by sex, age, latest CD4þ cell count and viral suppression (HIV-1 RNA
<400 copies/ml), were used to estimate expected age at death for ages 20–85 years.
Results: Of 21 388 patients who started ART, 961 (4.5%) died during 110 697 person-
years. At start of ART, expected age at death [95% confidence interval (CI)] of 35-year-
old men with CD4þ cell count less than 200, 200–349, at least 350 cells/ml was 71 (68–
73), 78 (74–82) and 77 (72–81) years, respectively, compared with 78 years for men in
the general UK population. Thirty-five-year-old men who increased their CD4þ cell
count in the first year of ART from less than 200 to 200–349 or at least 350 cells/ml and
achieved viral suppression gained 7 and 10 years, respectively. After 5 years on ART,
expected age at death of 35-year-old men varied from 54 (48–61) (CD4þ cell count
<200 cells/ml and no viral suppression) to 80 (76–83) years (CD4þ cell count
350 cells/ml and viral suppression).
Conclusion: Successfully treated HIV-positive individuals have a normal life expect-
ancy. Patients who started ART with a low CD4þ cell count significantly improve their
life expectancy if they have a good CD4þ cell count response and undetectable viral
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Life expectancy of HIV-positive individuals treated with
antiretroviral therapy (ART) in the UK improved by
nearly 16 years between 1996 and 2008 [1]. Although
some groups of HIV-positive individuals may expect to
live a similar life span to that of the general population,
others have reduced life expectancy due to the impact of
late diagnosis and late initiation of ART [1,2]. A previous
study estimated life expectancies of HIV patients in the
UK stratified by CD4þ cell count at ART start [1], but
not gains in years of life in response to ART [1]. A
European study showed that successfully treated patients
who attained a CD4þ cell count more than 500 cells/ml
have a standardized mortality ratio (SMR) approaching 1
[3]. However, SMRs are more difficult to communicate
to patients than life expectancies and not all patients attain
a CD4þ cell count more than 500 cells/ml [4,5]. The
lower limit of the normal CD4þ cell count range is below
500 cells/ml, and therefore exceeding this level might be
an unrealistic target for patients who had low preinfection
counts [6]. Furthermore, viral suppression is an important
factor in treatment success [7] and virological replication
may have an effect on prognosis that is independent of
CD4þ cell count [8,9].
We aimed to investigate the improvement in life
expectancy due to CD4þ cell count restoration and viral
suppression in patients on ART. We used data from the
UK Collaborative HIV Cohort (UK CHIC) Study, on
HIV-positive individuals in care in the UK between 2000
and 2012, to estimate life expectancy of those treated for
HIV-infection at different durations of ARTaccording to
latest CD4þ cell count and viral suppression status.Materials and methods
Cohort description
The UK CHIC Study was initiated in 2001 and collates
routine data on HIV-positive individuals aged 16 years or
over attending clinical centres in the UK since 1 January
1996 (see appendix) [10]. The project uses anonymized
data and was approved by a Multicentre Research Ethics
Committee and by local ethics committees.
Patient selection
Patients included in this analysis were aged 20 years and
over and started treatment with ARTwith at least three
drugs between 1 January 2000 and 31 December 2010
and were followed up until 31 December 2012.
Individuals whose assumed transmission was via injection
drug use or mother-to-child were excluded due to low
frequencies and worse prognosis compared with other
risk groups. Patients with missing baseline CD4þ cell
count were included in the study population. Patients
were followed up from ART start for all-cause mortality.pyright © Lippincott Williams & Wilkins. UnauthoDeaths were ascertained from clinic records and by
linkage to national surveillance data that use the UK civil
death registry. Patients were considered lost to follow-up
if they did not have a visit date within 2 years of database
close date and were not known to have died before 31
December 2012. Those lost to follow-up were censored
at the date of the last visit plus 3 months. Crude rate of
losses to follow-up was determined and characteristics of
patients who were and were not lost to follow-up were
compared.
Variable measurements
The latest CD4þ cell count before starting ART and the
last measured in the first, second, third, fourth and fifth
year of ARTwere determined for patients remaining in
follow-up. We determined whether patients were virally
suppressed (HIV-1 RNA <400 copies/ml) in the
previous year for those remaining under follow-up. For
the first year of ART, we used measurements of viral load
from 6 to 12 months duration of ART.
Statistical methods
Crude sex-specific mortality rates (per 1000 person-
years) were calculated overall and for those aged
20–44 years. Six Poisson models were used to estimate
mortality rates from start of ARTand for each duration of
ART (follow-up starting at 0, 1, 2, 3, 4 and 5 years after
ART start), by sex, age, latest CD4þ cell count (<200,
200–349, 350 cells/ml) and viral load (400 versus
>400 copies/ml). Abridged life tables were constructed
for each sex from age-specific mortality rates grouped in
5-year age bands and used to estimate life expectancy for
ages 20–85 years. These tables describe the mortality
experience that hypothetical cohorts of HIV-positive
individuals would have if they were subjected to the
mortality in the observed period. Life expectancy at an
exact age is defined as the average number of years
remaining among individuals who survived to the
specified age, according to the cross-sectional age-specific
all-cause mortality rates during the study period. In this
article, we present expected age at death instead of life
expectancy, as clinicians and patients have indicated a
preference for this. For example, if a 35-year-old has a life
expectancy of 40 years, their expected age at death would
be 75 years old. The main analyses estimated expected age
at death [95% confidence interval (95% CI)] for each sex
overall, and stratified by both achieved CD4þ cell count
and viral suppression status at exact ages 20, 35 and
50 years old. Secondary analyses estimated the effect on
expected age at death of attained CD4þ cell count
unadjusted for viral suppression and vice versa.
We used sex-specific mortality rates in the UK population
for 2000–2009 grouped in 5-year age bands to estimate
life expectancies of the general population (www.morta
lity.org). Life expectancies were compared for those with
attained CD4þ cell count 350–499 versus at least
500 cells/ml. Detailed information on the calculation ofrized reproduction of this article is prohibited.
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version 12 and Microsoft Excel 2008 to perform analyses.Results
The UK CHIC Study included data on 47 201 HIV-
positive individuals of whom 22 151 started ART
between 2000 and 2010. We excluded 568 (3%) IDU,
164 (0.7%) infected via mother-to-child transmission,
two patients without sex recorded and 29 aged less than
20 years, which left 21 388 eligible patients.
Table 1 summarizes the demographic and clinical
characteristics of patients at ART start by sex and the
proportion of patients with missing data for each
covariate. The majority of patients 14 742/21 388
(69%) were men, and of these, 10 246 (71%) were
MSM, and 9649 (67%) were of white ethnicity. In
contrast, nearly all the women 6265/6646 (97%) were
infected heterosexually and the majority 4778 (74%) wereCopyright © Lippincott Williams & Wilkins. Unaut
Table 1. Demographic and clinical characteristics of patients at start of
Variable N (%) Missing N (%) M
Ethnicity 375 (2.5)
White 9
Black African 2
Other 2
Age distribution (years) –
<30 2
30–39 6
40–49 4
50–59 1
60
Age median (IQR) (years)
Risk factor for transmission 364 (2.5)
MSM 10
Heterosexual 3
Blood
Other
AIDS CDC stage C diagnosis – 2
CD4þ cell count distribution (cells/ml) 2080 (14.1)
<200 7
200–349 4
350 2
CD4þ cell count Median (IQR)
HIV-1 RNA (log copies/ml) 2082 (14.1)
<4.00 2
4.00–4.99 4
5.00 5
HIV-1 RNA Median (IQR)
Initial drug regimen –
PI-based 3
NNRTI-based 10
Triple NRTI
Four or more drugs
Nonstandard regimen
Year of starting ART –
2000–2002 3
2003–2005 3
2006–2008 4
2009–2010 3
ART, antiretroviral therapy; IQR, interquartile range; NNRTI, nonnucleoside
inhibitor; PI, protease inhibitor.black African. The women were younger than the men
with very few aged 60 years or more.
During 110 697 person-years, 961/21 388 (4.5%) patients
died. The crude mortality rate of 9.0 per 1000 person-
years for men (95% CI 8.4–9.7) was higher than rate of
7.9 for women (7.0–8.9), but was the same in both sexes
for those aged less than 45 years [men 6.9 (6.2–7.7);
women 6.9 (6.0–7.9)]. Rate of losses to follow-up was
3.9 per 100 person-years. Compared with those retained
in care, patients lost to follow-up were more likely to be
men, infected through heterosexual contact or blood (or
unknown), black African, Asian or mixed race (or
unknown), younger, diagnosed with AIDS prior to
starting ART and had higher CD4þ cell count at ART
start, although median CD4þ cell count was similar
[retained in care 214 interquartile range (IQR 116–310);
lost 210 (108–320) cells/ml]. For the analyses taking into
account response to treatment in the first, second, third,
fourth and fifth years after starting ART, data were
available on 16 794/19 855 (85%), 15 604/17 400 (90%),
13 223/14 721 (90%), 11 032/12 201 (90%) and 9126/horized reproduction of this article is prohibited.
antiretroviral therapy by sex (NU21388).
en (N¼14742) Missing N (%) Women (N¼6646)
170 (2.6)
649 (67.2) 730 (11.3)
527 (17.6) 4778 (73.8)
191 (15.3) 968 (15.0)
–
214 (15.0) 1915 (28.8)
343 (43.0) 3000 (45.1)
435 (30.1) 1260 (19.0)
290 (8.8) 357 (5.4)
460 (3.1) 114 (1.7)
38 (32–44) 34 (29–40)
166 (2.5)
246 (71.3) –
531 (24.6) 6265 (96.7)
64 (0.4) 32 (0.5)
537 (3.7) 183 (2.8)
158 (14.6) – 1059 (15.9)
1086 (16.3)
035 (49.2) 2746 (49.4)
876 (34.1) 1734 (31.2)
375 (16.6) 1080 (19.4)
220 (121–313) 200 (100–310)
1150 (17.3)
899 (22.9) 2050 (37.3)
485 (35.4) 1937 (35.2)
276 (41.7) 1509 (27.5)
4.8 (4.1–5.3) 4.4 (3.4–5.1)
–
325 (22.6) 2053 (30.9)
157 (68.9) 4102 (61.7)
295 (2.0) 202 (3.0)
736 (5.0) 231 (3.5)
229 (1.6) 58 (0.9)
–
046 (20.7) 1484 (22.3)
763 (25.5) 2013 (30.3)
652 (31.6) 1974 (29.7)
281 (22.3) 1175 (17.7)
reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase
Co
1196 AIDS 2014, Vol 28 No 810 030 (91%) patients, respectively, who had appropriate
CD4þ cell count and viral load measurements in those
years and had subsequent follow-up time.
Overall estimates of expected age at death from
antiretroviral therapy start compared with the
UK general population
The expected age at death for HIV-positive men from
ART start was 68 (66–71), 73 (71–76) and 77 (75–80)
years at exact ages 20, 35 and 50 years, respectively,
compared with 77, 78 and 79 years in the general
population. The corresponding expected age at death for
HIV-positive women was 69 (65–73), 74 (70–78) and 78
(73–82) years, compared with 81, 82 and 83 years in the
general population.
Effect of CD4R cell count and viral suppression
on life expectancies
Expected age at death (95% CI) for men (Table 2) and
women (Table 3) showed a graded association with both
attained CD4þ cell count and viral suppression status. At
ART start, a 35 year-old man with CD4þ cell count less
than 200 cells/ml could expect to live to 71 (68–73) years,
over 7 years less than men in the general UK population.
Such a patient who achieved viral suppression and
increased their CD4þ cell count in the first year of ART
to 200–349 or at least 350 cells/ml increased their
expected age at death to 78 (74–82) or 81 (77–84) years,
respectively. This is comparable with the general popu-
lation male life expectancy of 78 years. After 5 years on
ART, expected age at death of 35-year-old men varied
from 54 (48–61) to 80 (76–83) years for those with
CD4þ cell count less than 200 cells/ml and no viral
suppression versus CD4þ cell count at least 350 cells/ml
and suppressed. Figures 1 (men) and 2 (women) illustrate
that within each CD4þ cell count strata, expected age at
death is higher for those with than those without viral
suppression.
Compared with men at ART start, the expected age at
death was between 3 and 4 years greater for those who
survived 5 years on ART (Table 2), depending on their
current age. Life expectancy was higher for women
reflecting the higher life expectancy of women in the
general population (Table 3). There was no difference in
mortality between those with CD4þ cell count 350–499
and at least 500 cells/ml for either men or women.
Median CD4þ cell count increased with duration of ART
and was higher in those with viral suppression
(Supplementary figure 1, http://links.lww.com/QAD/
A495). The proportion of patients with CD4þ cell count
at least 350 cells/ml increased markedly in the first year of
ART, and continued to increase up to 5 years on ART
(Supplementary figure 2, http://links.lww.com/QAD/
A495). Only 19% of patients had CD4þ cell count more
than 350 cells/ml at ART start, compared with 79% ofpyright © Lippincott Williams & Wilkins. Unauthopatients on ART for more than 5 years, with 52% having
CD4þ cell count more than 500 cells/ml.
Mortality rates per 1000 person years among younger
men decreased with increasing CD4þ cell count and were
lower in patients with viral suppression. Mortality rates
overall, and restricted to those aged 20–44 years, for
different durations of ART, and stratified by CD4þ cell
count and viral suppression, are summarized in supple-
mentary Tables 4 (men) and 5 (women), http://
links.lww.com/QAD/A495. After 5 years on ART,
mortality rates among younger men varied from 2.7
(1.7–4.3) (viral suppression/high CD4þ cell count) to
38.1 (21.1–68.9) (unsuppressed/low CD4þ cell count).
Of those who died, 20% did not have a clinic visit
recorded in the previous 6 months and 11% had been out
of care for more than 1 year.
Secondary analyses show the contributions of viral
suppression unadjusted for CD4þ cell count (supple-
mentary table 6, http://links.lww.com/QAD/A495) and
CD4þ cell count unadjusted for viral suppression
(supplementary table 7, http://links.lww.com/QAD/
A495) to decrease in life expectancy of men. After 5 years
on ART, 20-year-old men would be expected to live on
average to age 75 years if virally suppressed and to 59 years
without suppression. Viraemia at the previous visit was
undetectable in 88% of patients on ART for 5 years.
Compared to 20 year-old men with viral suppression,
those without viral suppression had life expectancies that
were 11 and 16 years shorter after 1 and 5 years of ART,
respectively.
At ART start, 20-year-old men with CD4þ cell count less
than 200, 200–349, at least 350 cells/ml were estimated to
live on average to 65 (61–68), 74 (69–79) and 72 (67–77)
years, respectively. After 5 years on ART, expected age at
death was 50 (38–63), 72 (64–79) and 75 (70–81) years
depending on whether their attained CD4þ cell count
was less than 200, 200–349 or at least 350 cells/ml,
respectively (supplementary table 7, http://links.lww.
com/QAD/A495). Patterns for women were similar
(data not shown).Discussion
Successfully treated patients who achieved viral suppres-
sion and attained a CD4þ cell count of at least 350 cells/
ml within 1 year of starting ART had a normal life
expectancy, with a 35-year-old HIV-positive person
estimated to live to about 80 years on average. Patients
with CD4þ cell count less than 200 cells/ml, either before
or after starting ART, were at an increased risk of death:
the difference in life expectancy between those with
attained CD4þ cell count less than 200 compared with at
least 200 cells/ml was 8 years at ART start and widenedrized reproduction of this article is prohibited.
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
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Fig. 1. Expected age at death of men aged 35 years at
different durations of antiretroviral therapy according to
current CD4R cell count and viral suppression compared
with the general population.with duration of ART. Although most of the effect of
viral suppression on decreasing mortality is likely to be
mediated through increasing CD4þ cell count, never-
theless there remained an independent effect of detectable
viral load on life expectancy. Those with CD4þ cell count
less than 200 cells/ml at 5 years after starting ART lost
between 15 and 26 potential years of life depending on
whether they were or were not virally suppressed.
Strengths and limitations of study
We analysed data on over 20 000 patients on ART, among
whom there were nearly a thousand deaths. Our study
was based on a cohort that included approximately 34% of
patients in usual care for HIV infection in UK and
therefore our estimates of expected age at death should be
applicable to patients on ART in the UK. In 2012–2013,
UK CHIC undertook extensive linkage with databasesCopyright © Lippincott Williams & Wilkins. Unaut
0
55
60
65
70
75
80
85
1 2 3
Years since start of ART
Female UK LE 82 years
VL ≤ 400
CD4+ ≥ 350
CD4+ 200- 349
CD4+ < 200
VL > 400
CD4+ ≥ 350
CD4+ 200- 349
CD4+ < 200
4 5
Ex
pe
ct
ed
 a
ge
 a
t d
ea
th
 (y
e
a
rs
)
Fig. 2. Expected age at death of women aged 35 years at
different durations of antiretroviral therapy according to
current CD4R cell count and viral suppression compared
with the general population.held at Public Health England (PHE) in order to validate
the reporting of deaths by the participating hospital clinics
and to include deaths missing from HIV clinic records
(approximately 16% of all deaths), which were reported in
the UK civil death register. Therefore completeness of
death ascertainment should be high [11]. However, as
many patients were lost to follow-up, there remains the
possibility of missed deaths, which would bias estimates of
expected age at death upwards. As expected, patients lost
to follow-up were more likely to have characteristics
associated with migrant backgrounds and some may have
returned to their country of origin now that ART is more
widely available, particularly in sub-Saharan Africa.
Analyses of those lost to follow-up were inconclusive
in determining whether lost patients were likely to have
lower or higher mortality than those remaining in care.
Reasons for losses to follow-up are varied and as well as
including dropping out of care and deportation, also
include transferring care to another ART provider, either
in the UK, but not contributing to UK CHIC, or abroad.
Although there was some evidence that, compared with
those who remained in the study, those who dropped out
were sicker (positive association with AIDS diagnosis),
other associations implied that a well group were also lost
to follow-up (younger and having a higher CD4þ cell
count). As in a French study [12], men were more likely
to be lost than women, which could be because men are a
more mobile population. In each time period considered,
only patients with data on CD4þ cell count and viral load
measurements could be included, which led to around
10% of patients being excluded from each model.
Therefore, our results may only apply to patients
remaining in regular care in the UK, but this will be
the majority of HIV-positive individuals in the con-
tinuum of care [13]. Our estimates of life expectancy only
used age and sex-adjusted estimates of mortality rates that
were stratified by response to ART determined by
attained CD4þ cell count and viral suppression status. A
greater range of variables, including non-HIV bio-
markers, have been used in prognostic models that aim to
define short-term prognosis rather cancy [7,14–17].
Estimated life expectancy may be biased by extrapolation
beyond available data. There were few patients aged more
than 60 years (<3% of the total) and therefore estimates of
mortality rates at older ages are imprecise, particularly in
women. We compensated for this by using Poisson
regression models to estimate mortality rates, which
borrowed strength from trends across age and sex. Thus,
we ensured that the rates used in lifetables were smoother
than crude sex and age-specific rates would have been.
However, this also constrained mortality patterns to be
similar for men and women, which may not be true. In
using lifetables, we are assuming that age-specific
mortality rates estimated from the current population
can be used as if they will apply within individuals
throughout their lives. However, these estimates are based
on a population that has experienced a maximumhorized reproduction of this article is prohibited.
Co
1200 AIDS 2014, Vol 28 No 8duration of ART of 12 years, whereas a current patient
who starts ART at age 35 years will, for example,
when they are aged 60 experience the mortality rates of a
60 year-old conditional on having taken ART for
25 years. Possible scenarios that have been considered in a
modelling exercise are that there will be long-term toxic
effects of ARTor that patients will run out of treatment
options due to drug resistance [18]. On the contrary, in
the future, better ART drugs may be developed or less
toxic combinations used. In particular, NRTI-sparing
regimens may reduce long-term toxicities. Currently,
there is considerable interest and ongoing trials in ART
simplification strategies [19], such as using a single
boosted protease inhibitor as a maintenance regimen in
those who are stable and virologically suppressed on ART
[20], which will also reduce the cost of lifelong ART.
Discussion of findings in context
In response to the Health and Social Care Act 2012 [21],
PHE has implemented a new scheme for monitoring the
success of ART, which assesses both the proportion of
patients with viral suppression and the proportion with
CD4þ cell count at least 350 cells/ml; our study shows
that both are associated with mortality risk and lost years
of life. Although better immunological function is
critical for avoiding AIDS-related mortality and may
be important for avoiding some non-AIDS cancers
[22–24], the inflammatory effect of viral replication may
be also be associated with excess mortality, and in
particular the SMART study showed an increased risk
from cardiovascular disease with higher levels of
interleukin-6, C-reactive protein and D-dimer [25].
Mendelian randomization studies suggest that interleu-
kin-6 [26], but not C-reactive protein [27], is causally
associated with coronary heart disease in the general
population. Further research is required to establish
whether any of the associations of these biomarkers of
inflammation with mortality are causal in HIV-infected
populations.
During the study period, guidelines recommended
starting ART once CD4þ cell count had fallen below
350 cells/ml unless treatment was required for prevention
of mother-to-child transmission or in the case of an AIDS
diagnosis or other particular health need [28]. This
explains the paradoxical finding that life expectancy from
ART start was lower in those who started with CD4þ cell
count at least 350 compared with 200–349 cells/ml; they
would have been a highly selected group. However, with
the move towards treatment as prevention [29] and the
change in WHO guidelines to starting at CD4þ cell
count below 500 cells/ml [30], it is likely that more people
in the UK will start ARTat higher CD4þ cell count even
if asymptomatic. The current 2012 British HIV
Association guidelines [31] continue to recommend that
ART is started once CD4þ cell count has fallen below
350 cells/ml but allow for treatment above this thresholdpyright © Lippincott Williams & Wilkins. Unauthoto reduce the risk of transmission to partners if the patient
wishes to start ART.
The predicted longevity is dependent on successfully
navigating the continuum of care, which requires
diagnosis of HIV infection before severe immunosup-
pression, prompt linkage to care, timely initiation of
treatment, good adherence to ARTand retention in care
[1,32]. Although at later durations of ART, attained is
more important than nadir CD4þ cell count, it is
important to realize that estimated life expectancies are
conditional on surviving the first year of ART and this is
highly dependent on nadir CD4þ cell count [14].
Furthermore, our analysis does not include individuals
who never start ART, which will exclude some
individuals with the poorest prognosis. Our study
supports a previous analysis which showed that patients
successfully treated with ART should be eligible for life
insurance at affordable premiums [33].
Our study is observational, and therefore associations of
CD4þ cell count and viral suppression with differences in
life expectancy may not be causal. We have not examined
whether patients have stopped ART, are poorly adherent
or have other risk factors for higher mortality. Failure to
attain an adequate CD4þ cell count or suppressed viral
load may be due to failure of the ART regimen and
resistance developing, or due to patients being unable or
unwilling to take the treatment [34], but it could also be
associated with other lifestyle, behavioural or clinical
factors that lead to a higher underlying mortality. HIV-
positive populations generally have a higher prevalence of
smoking [35], alcohol [36] and illicit drug abuse [37,38],
and hepatitis B and C coinfection, which are risk factors
for mortality and may be associated with lower attained
CD4þ cell count and higher viral load [39–41].
Nevertheless, our results indicate that those with
CD4þ cell count at least 350 cells/ml and suppressed
viral load have a life expectancy slightly higher than the
general population. This could be due to missing deaths
or it could be real, as this population is in clinical care and
frequently monitored and therefore might receive better
management of chronic disease risk factors and earlier
diagnosis of other diseases, such as cancer, compared with
the general population. In a combined analysis of well
controlled HIV-infected adults in the SMART and
ESPRIT clinical trials in which ascertainment of death
should be less affected by losses to follow-up, SMR
estimates for patients with viral suppression and
CD4þ cell count at least 350 cells/ml varied between 1
(0.73–1.34) and 1.57 (1.26–1.94) depending on the
criteria used for including follow-up time [9]. SMR
estimates were higher for CD4þ cell count between 350
and 499 compared with at least 500 cells/ml, but CIs
overlapped [9]. In our study of patients in usual clinical
care, we found no strong evidence of differences in
mortality rates between these CD4þ cell count categories
and therefore did not estimate life expectancy separately.rized reproduction of this article is prohibited.
Life expectancy and response to antiretroviral therapy May et al. 1201Conclusion
In the UK, where ART is free and available in an
established National Health Service, people living with
HIV infection can expect to live as long as the general
population if successfully treated. Our study showed that
longevity depends on both restoration of CD4þ cell
count to near normal levels and suppression of the virus to
undetectable levels in peripheral blood.Acknowledgements
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